Certara Corrects EBITDA Disclosure in Earnings Presentation
Certara announced a correction to its second-quarter 2026 earnings presentation regarding the adjusted EBITDA of its recently divested Regulatory and Medical Writing business. The company clarified that the business generated approximately $23 million of adjusted EBITDA in 2025 when excluding unallocated corporate expenses, a …